Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

“I literally had to buy everything new from bathing suits to pants to shirts.” Dr. Carroll says ... approved for the treatment of diabetes. Eli Lilly then came up with a second-generation ...

(Even larger is U.S.-based Eli Lilly & Co. the maker of Zepbound and ... Impact Analytics found that sales for smaller-sized women’s shirts increased by 12.1%, based on a survey of New York ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...